In summary, our results showed that when an AAV carrying the CD4-CAR gene was infused into mice, it could quickly reprogram lymphocytes and generate sufficient CAR cells to induce ATL regression in NCG-HuPBL mice, suggesting that ACG could be a potential strategy for tumor treatment. Here, CD4 is linked to neoplasm.